THE SHORT VERSION
- Discuss a planned pregnancy before stopping contraception.
- If pregnancy happens during treatment, contact your prescriber promptly.
Plan the medicine-free interval
Official UK advice is to stop tirzepatide at least one month before trying for pregnancy and semaglutide at least two months before. These intervals differ; do not use one rule for every GLP-1 product.
Ask your clinician to write down the timing, contraception plan and any alternative treatment. If you also have diabetes, maintaining appropriate blood-sugar care is particularly important. Do not independently stop other diabetes medicines when arranging this change.
If you discover you are pregnant
Stop the weight-management medicine and contact your prescriber or GP promptly. Tell them the product, when you last used it and the pregnancy dates you know. UKTIS/BUMPS advises stopping GLP-1 treatment used for weight loss when pregnancy is discovered; your team can arrange diabetes treatment if needed.
Exposure does not mean harm has definitely occurred. Ask for an individual discussion of the evidence and follow-up. Avoid answering the risk question from social-media anecdotes. Keep the pack details so your maternity team can document the exposure accurately.
Sources you can check
- UKTIS/BUMPS: GLP-1 receptor agonists in pregnancy
- MHRA: GLP-1 medicines safety guidance
- Mounjaro KwikPen: current UK patient leaflet
- Wegovy FlexTouch: current UK patient leaflet
Editorial presentation updated 24 October 2026. This is general information, not individual medical advice or a claim of independent clinical review. Read the linked source and the leaflet supplied with your medicine for the full context. Suggest a correction.